The estimated Net Worth of Nancy Denyes is at least 505 千$ dollars as of 5 February 2024. Ms Denyes owns over 2,688 units of Atyr Pharma Inc stock worth over 28,057$ and over the last 6 years she sold LIFE stock worth over 0$. In addition, she makes 477,136$ as Gen. Counsel & Corp. Sec. at Atyr Pharma Inc.
Ms has made over 4 trades of the Atyr Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 2,688 units of LIFE stock worth 5,107$ on 5 February 2024.
The largest trade she's ever made was exercising 12,500 units of Atyr Pharma Inc stock on 16 May 2019 worth over 23,750$. On average, Ms trades about 1,564 units every 144 days since 2019. As of 5 February 2024 she still owns at least 14,767 units of Atyr Pharma Inc stock.
You can see the complete history of Ms Denyes stock trades at the bottom of the page.
Nancy E. Denyes Krueger is the Gen. Counsel & Corp. Sec. at Atyr Pharma Inc.
As the Gen. Counsel & Corp. Sec. of Atyr Pharma Inc, the total compensation of Ms Krueger at Atyr Pharma Inc is 477,136$. There are 3 executives at Atyr Pharma Inc getting paid more, with Dr. Sanjay S. Shukla having the highest compensation of 702,046$.
Ms Krueger is 53, she's been the Gen. Counsel & Corp. Sec. of Atyr Pharma Inc since . There are 8 older and 3 younger executives at Atyr Pharma Inc. The oldest executive at Atyr Pharma Inc is Paul Schimmel, 79, who is the Independent Director.
Nancy's mailing address filed with the SEC is 10240 SORRENTO VALLEY ROAD, SUITE 300, , SAN DIEGO, CA, 92121.
Over the last 16 years, insiders at Atyr Pharma Inc have traded over 27,288,922$ worth of Atyr Pharma Inc stock and bought 966,653 units worth 5,761,237$ . The most active insiders traders include James C Blair、Gregory T Lucier、Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of 34,257$. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth 8,950$.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Atyr Pharma Inc executives and other stock owners filed with the SEC include: